Literature DB >> 22083261

Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy.

Birte Kalveram1, Olga Lihoradova, Sabarish V Indran, Tetsuro Ikegami.   

Abstract

Rift Valley fever virus (RVFV), which causes hemorrhagic fever, neurological disorders or blindness in humans, and a high rate abortion and fetal malformation in ruminants, has been classified as a HHS/USDA overlap select agent and a risk group 3 pathogen. It belongs to the genus Phlebovirus in the family Bunyaviridae and is one of the most virulent members of this family. Several reverse genetics systems for the RVFV MP-12 vaccine strain as well as wild-type RVFV strains, including ZH548 and ZH501, have been developed since 2006. The MP-12 strain (which is a risk group 2 pathogen and a non-select agent) is highly attenuated by several mutations in its M- and L-segments, but still carries virulent S-segment RNA, which encodes a functional virulence factor, NSs. The rMP12-C13type (C13type) carrying 69% in-frame deletion of NSs ORF lacks all the known NSs functions, while it replicates as efficient as does MP-12 in VeroE6 cells lacking type-I IFN. NSs induces a shut-off of host transcription including interferon (IFN)-beta mRNA and promotes degradation of double-stranded RNA-dependent protein kinase (PKR) at the post-translational level. IFN-beta is transcriptionally upregulated by interferon regulatory factor 3 (IRF-3), NF-kB and activator protein-1 (AP-1), and the binding of IFN-beta to IFN-alpha/beta receptor (IFNAR) stimulates the transcription of IFN-alpha genes or other interferon stimulated genes (ISGs), which induces host antiviral activities, whereas host transcription suppression including IFN-beta gene by NSs prevents the gene upregulations of those ISGs in response to viral replication although IRF-3, NF-kB and activator protein-1 (AP-1) can be activated by RVFV7. Thus, NSs is an excellent target to further attenuate MP-12, and to enhance host innate immune responses by abolishing the IFN-beta suppression function. Here, we describe a protocol for generating a recombinant MP-12 encoding mutated NSs, and provide an example of a screening method to identify NSs mutants lacking the function to suppress IFN-beta mRNA synthesis. In addition to its essential role in innate immunity, type-I IFN is important for the maturation of dendritic cells and the induction of an adaptive immune response. Thus, NSs mutants inducing type-I IFN are further attenuated, but at the same time are more efficient at stimulating host immune responses than wild-type MP-12, which makes them ideal candidates for vaccination approaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083261      PMCID: PMC3308613          DOI: 10.3791/3400

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  32 in total

Review 1.  Links between innate and adaptive immunity via type I interferon.

Authors:  Agnes Le Bon; David F Tough
Journal:  Curr Opin Immunol       Date:  2002-08       Impact factor: 7.486

Review 2.  Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation.

Authors:  David F Tough
Journal:  Leuk Lymphoma       Date:  2004-02

3.  Mechanism of tripartite RNA genome packaging in Rift Valley fever virus.

Authors:  Kaori Terasaki; Shin Murakami; Kumari G Lokugamage; Shinji Makino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection.

Authors:  Sonja R Gerrard; Brian H Bird; Cesar G Albariño; Stuart T Nichol
Journal:  Virology       Date:  2006-10-30       Impact factor: 3.616

5.  Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs.

Authors:  M Bouloy; C Janzen; P Vialat; H Khun; J Pavlovic; M Huerre; O Haller
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

7.  Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis.

Authors:  J D Mosca; P M Pitha
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

8.  Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex.

Authors:  S N Constantinescu; E Croze; A Murti; C Wang; L Basu; D Hollander; D Russell-Harde; M Betts; V Garcia-Martinez; J E Mullersman; L M Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease.

Authors:  Brian H Bird; César G Albariño; Stuart T Nichol
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

10.  Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

View more
  22 in total

1.  A ΩXaV motif in the Rift Valley fever virus NSs protein is essential for degrading p62, forming nuclear filaments and virulence.

Authors:  Normand Cyr; Cynthia de la Fuente; Lauriane Lecoq; Irene Guendel; Philippe R Chabot; Kylene Kehn-Hall; James G Omichinski
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

2.  Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.

Authors:  Shoko Nishiyama; Olga A L Slack; Nandadeva Lokugamage; Terence E Hill; Terry L Juelich; Lihong Zhang; Jennifer K Smith; David Perez; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Virulence       Date:  2016-06-01       Impact factor: 5.882

3.  Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Authors:  Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

4.  Toscana virus NSs protein promotes degradation of double-stranded RNA-dependent protein kinase.

Authors:  Birte Kalveram; Tetsuro Ikegami
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

5.  Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.

Authors:  Kimberly K Roberts; Terence E Hill; Melissa N Davis; Michael R Holbrook; Alexander N Freiberg
Journal:  J Gen Virol       Date:  2015-03-10       Impact factor: 3.891

6.  The NSs Protein Encoded by the Virulent Strain of Rift Valley Fever Virus Targets the Expression of Abl2 and the Actin Cytoskeleton of the Host, Affecting Cell Mobility, Cell Shape, and Cell-Cell Adhesion.

Authors:  Aline Bamia; Vasco Marcato; Magali Boissière; Zeyni Mansuroglu; Carole Tamietti; Mattea Romani; Dominique Simon; Guanfang Tian; Florence Niedergang; Jean-Jacques Panthier; Marie Flamand; Sylvie Souès; Eliette Bonnefoy
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

7.  Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.

Authors:  Hoai J Ly; Shoko Nishiyama; Nandadeva Lokugamage; Jennifer K Smith; Lihong Zhang; David Perez; Terry L Juelich; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Vaccine       Date:  2017-10-20       Impact factor: 3.641

8.  The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.

Authors:  Shoko Nishiyama; Nandadeva Lokugamage; Tetsuro Ikegami
Journal:  J Virol       Date:  2016-01-27       Impact factor: 5.103

9.  Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.

Authors:  Sabarish V Indran; Olga A Lihoradova; Inaia Phoenix; Nandadeva Lokugamage; Birte Kalveram; Jennifer A Head; Bersabeh Tigabu; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  J Gen Virol       Date:  2013-03-20       Impact factor: 3.891

10.  Functional analysis of Rift Valley fever virus NSs encoding a partial truncation.

Authors:  Jennifer A Head; Birte Kalveram; Tetsuro Ikegami
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.